- $809.48m
- $446.93m
- $228.29m
- 68
- 42
- 51
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 50.7 | 98.4 | 149 | 185 | 228 |
Cost of Revenue | |||||
Gross Profit | 35.1 | 79.8 | 119 | 127 | 139 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 55.8 | 82.3 | 177 | 237 | 303 |
Operating Profit | -5.09 | 16.1 | -28 | -51.7 | -75.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.23 | 3.25 | -46.8 | -47.3 | -58.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.26 | 3.06 | -42.3 | -46 | -58.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.26 | 3.06 | -42.3 | -46 | -58.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.39 | 0 | -42.3 | -46 | -58.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.059 | 0 | -0.342 | -0.277 | -0.329 |
Dividends per Share |